Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05183646 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
A Phase 3 study of FSGS, sponsored by Dimerix Bioscience Pty.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
- 20
- Study locations
NCT05183646 is a Phase 3 study of FSGS that is actively recruiting participants, run by Dimerix Bioscience Pty. The registered enrollment target is 286 participants, above the 222-participant average among 4 other FSGS trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT05183646, a Phase 3 study of FSGS, is actively recruiting participants, sponsored by Dimerix Bioscience Pty.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
- 20
- Study locations
Study Summary
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB. Given the rarity of the disease and the similarities between adults and pediatric patients with FSGS, Dimerix will also investigate the efficacy and safety of DMX 200 in adolescents aged 12 to 17 years. The double-blind period will be followed by an open-label extension (OLE) which aims to assess the long-term efficacy and safety of DMX 200 for up to 2 additional years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DMX-200
Study Locations (20)
California
- Loma Linda University Medical Center - Loma Linda
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Los Angeles - Los Angeles
- Amicis Research Centre - Northridge
- Northridge Clinical Research Inc. - Northridge
- Kaiser Permanente - Oakland
- University of California Davis Health System - Sacramento
- Scripps Health - San Diego
- Stanford Hospital and Clinic - Stanford
Florida
- South Florida Nephrology Group, P.A. - Coral Springs
- Nicklaus Children's Hospital - Miami
- CTR Oakwater LLC - Orlando
Arizona
- Phoenix Children's Hospital - Phoenix
- Arizona Kidney Disease and Hypertension Center - Phoenix
Colorado
- University of Colorado Anschutz Medical Campus - Denver
- Denver Nephrology Research Division - Denver
Georgia
- Emory University School of Medicine - Atlanta
- Georgia Nephrology - Lawrenceville
Alabama
- University of Alabama at Birmingham - Birmingham
Idaho
- Boise Kidney - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05183646
The ClinicalTrials.gov registry entry for NCT05183646 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 222-participant average among 4 other FSGS trials with a reported enrollment target (29% higher). The listed sponsor is Dimerix Bioscience Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with FSGS appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05183646 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05183646 about?
NCT05183646 is a clinical study titled "A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB". DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind s...
What is the current status of trial NCT05183646?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2022-05-30. Estimated completion is 2029-12.
What conditions does trial NCT05183646 study?
This clinical trial studies the following conditions: FSGS.
What interventions are being tested in trial NCT05183646?
The interventions under investigation include: Placebo (DRUG), DMX-200 (DRUG).
Who is sponsoring clinical trial NCT05183646?
This trial is sponsored by Dimerix Bioscience Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05183646 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for FSGS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
-
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
RECRUITING · Phase 1
-
Atacicept in Multiple Glomerular Diseases
RECRUITING · Phase 2
-
NEPTUNE Match Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.